laboratori corpor america hold
diagnost tool
like persist reiter hold pt
labcorp deliv mix result today affirm neutral stanc stock
compani continu face pressur relat pama reimburs side
volum loss commerci contract side said covanc deliv
mid-to-upp singl digit growth compani demonstr traction
combin lab/drug develop strategi acknowledg lh reason valu
consensu earn think fair valuat attribut
stock ytd return year benefit includ
index given discount index reiter hold pt
use multipl adj ep
disappoint dtc test lh dtc test volum deliv
first y/i declin mark drag lh organ volum lh continu
expect dtc volum flat forese futur respons
question call lh opin take year know long-term
valu dtc market health applic came bit surpris us
cautiou recoveri dtc space suspect may
upgrad technolog enabl greater health insight patient reduc
test discount lower tv ad spend on-going weak dtc test
help lh would much detriment hold-rat orasur
buy-rat host call come day
rev y/i
street driven organ revenue growth
respect partial off-set neg impact divestitur
fx adj ep y/i miss beat street
labcorp diagnost dx rev y/i miss driven
hit pama declin organ volum due
headwind lower consum genet demand manag care loss
covanc covanc rev y/i beat y/i
driven organ growth growth off-set
neg impact fx neg impact divestitur om covanc
y/i covanc backlog exit increas
sequenti lh expect backlog convert revenu ntm lh
realiz cost synergi chiltern integr expect drive
addit net cost synergi envigo lh track goal
drive net save covanc launchpad program
tighten guid lh narrow revenue guid y/i
diagnost revenue guid includ
impact food solut divestitur lh narrow covanc revenue
growth guid y/i includ impact
fx lh narrow adj ep guid y/i
flat y/i vs our/street prior lh maintain
guid share buy-back author remain
price close busi juli
labcorp lead refer laboratori test
compani also oper covanc drug develop
chiltern
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
new lab act revers pama pain investor prudenc warrant
assum chang statu quo pama pain cautious optimist
potenti new lab act bill introduc hous last month
could possibl delay next round data report one year
expand scope applic lab includ hospit lab would
result better reimburs lh bill mark progress made acla
view odd pama fix zero view lab act free call option
pama fix
share-shift start play competitor quest deliv strong
volum growth lh report volum exclud divestitur
organ volum declin lh call impact manag
care chang indic earlier week expect volum growth build
primarili new live target opportun time
said lh indic saw largest impact volum loss relat
quest saw trend stabil
envigo mid-april lh announc acquisit envigo nonclin research
servic busi cash envigo rev envigo
busi includ facil eu us increas covanc nonclin
research employe base employe global
lh select prefer lab unit lh lost lab exclus
select one prefer lab along quest
ameripath/dermpath subsidiari biorefer lab genedx
mayo clinic lab join prefer lab network pln
recent went effect juli
covanc deliv line lh expect lh drove solid top line growth
covanc busi y/i deliv book-to-bil slight uptick
prior quarter exit backlog
expect convert revenu next month lh look covanc drive
total compani revenu growth guid revenu growth core
diagnost segment
 buyback key compon lh capit deploy repurchas
stock lh author buy-back plan bought back
lh indic light year
activ expect featur increas tuck-in deal lh discuss
sever health system believ industri awar impact pama
risen
consum initi move forward lh indic call plan
open least site store end labcorp walgreen
partnership indic track open least locat
cover compani mention report
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
laboratori corpor america hold
diagnost tool
laboratori corpor america hold
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
laboratori corpor america hold lh
pt use multipl adj ep estim
pt use multipl adj ep estim y/i
pt use multipl adj ep estim
pt use multipl revenu estim million discount back year plu net
risk achiev target price valuat
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
diagnost tool
laboratori corpor america hold
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
